Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Perrone

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2017
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control StudyFilippo Pietrantonio, Giovanni Fucà, Federica Morano, et al.
Cancer Medicine|December 2, 2024
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic CancerFederico Nichetti, Marco Silvestri, Luca Agnelli, et al.
International Journal of Cancer|June 20, 2022
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based studyMonica Niger, Federico Nichetti, Andrea Casadei-Gardini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2019
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerFilippo Pietrantonio, Riccardo Lobefaro, Maria Antista, et al.
JCO Precision Oncology|July 24, 2023
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient CareAndrea Vingiani, Luca Agnelli, Matteo Duca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA TrialFederica Morano, Alessandra Raimondi, Filippo Pagani, et al.
Molecular Oncology|May 27, 2022
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancersMonica Niger, Federico Nichetti, Andrea Casadei-Gardini, et al.
Neuroendocrinology|November 23, 2022
Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled AnalysisGiovanni Centonze, Patrick Maisonneuve, Natalie Prinzi, et al.
Tumori|July 10, 2025
Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patientsDaniele Lorenzini, Gabriella Gaudioso, Alessandro Scardoni, et al.
Human Mutation|December 24, 2016
TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral SclerosisJulie van der Zee, Ilse Gijselinck, Sara Van Mossevelde, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2017
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control StudyFilippo Pietrantonio, Giovanni Fucà, Federica Morano, et al.
Cancer Medicine|December 2, 2024
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic CancerFederico Nichetti, Marco Silvestri, Luca Agnelli, et al.
International Journal of Cancer|June 20, 2022
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based studyMonica Niger, Federico Nichetti, Andrea Casadei-Gardini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2019
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerFilippo Pietrantonio, Riccardo Lobefaro, Maria Antista, et al.
JCO Precision Oncology|July 24, 2023
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient CareAndrea Vingiani, Luca Agnelli, Matteo Duca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA TrialFederica Morano, Alessandra Raimondi, Filippo Pagani, et al.
Molecular Oncology|May 27, 2022
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancersMonica Niger, Federico Nichetti, Andrea Casadei-Gardini, et al.
Neuroendocrinology|November 23, 2022
Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled AnalysisGiovanni Centonze, Patrick Maisonneuve, Natalie Prinzi, et al.
Tumori|July 10, 2025
Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patientsDaniele Lorenzini, Gabriella Gaudioso, Alessandro Scardoni, et al.
Human Mutation|December 24, 2016
TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral SclerosisJulie van der Zee, Ilse Gijselinck, Sara Van Mossevelde, et al.
Pageof 16